These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 6226242)

  • 1. In vitro and in vivo antibacterial activity of AT-2266.
    Kouno K; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1983 Jul; 24(1):78-84. PubMed ID: 6226242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.
    Nakamura S; Minami A; Katae H; Inoue S; Yamagishi J; Takase Y; Shimizu M
    Antimicrob Agents Chemother; 1983 May; 23(5):641-8. PubMed ID: 6575721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antibacterial activity of AM-715, a new nalidixic acid analog.
    Ito A; Hirai K; Inoue M; Koga H; Suzue S; Irikura T; Mitsuhashi S
    Antimicrob Agents Chemother; 1980 Feb; 17(2):103-8. PubMed ID: 6446258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of AT-2266 compared with those of norfloxacin, pipemidic acid, nalidixic acid, and gentamicin against various experimental infections in mice.
    Nakamura S; Nakata K; Katae H; Minami A; Kashimoto S; Yamagishi J; Takase Y; Shimizu M
    Antimicrob Agents Chemother; 1983 May; 23(5):742-9. PubMed ID: 6223579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of enoxacin compared with norfloxacin and amikacin.
    van der Auwera P; de Moor G; Lacroix G; Mambour A; Rossion N; Schuyteneer F
    Eur J Clin Microbiol; 1985 Feb; 4(1):55-8. PubMed ID: 3157568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.
    Chartrand SA; Scribner RK; Weber AH; Welch DF; Marks MI
    Antimicrob Agents Chemother; 1983 May; 23(5):658-63. PubMed ID: 6223577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.
    Muytjens HL; van der Ros-van de Repe J; van Veldhuizen G
    Antimicrob Agents Chemother; 1983 Aug; 24(2):302-4. PubMed ID: 6227281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
    Traub WH
    Chemotherapy; 1985; 31(1):34-9. PubMed ID: 3156026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activity of seven gyrase inhibitors of a group of heterocyclic carbonic acids against nonfermenting gram negative rods (nonfermenters)].
    Grimm H
    Arzneimittelforschung; 1985; 35(3):570-2. PubMed ID: 2986655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro comparison of norfloxacin with nalidixic acid, cinoxacin and oxolinic acid.
    Vuye A
    Arzneimittelforschung; 1983; 33(12):1623-7. PubMed ID: 6230083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the antibacterial in vitro and in vivo activity of ofloxacin (HOE 280 DL 8280) and nalidixic acid analogues.
    Seibert G; Limbert M; Klesel N
    Eur J Clin Microbiol; 1983 Dec; 2(6):548-53. PubMed ID: 6230226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.
    Chin NX; Neu HC
    Antimicrob Agents Chemother; 1983 Nov; 24(5):754-63. PubMed ID: 6229216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
    Bauernfeind A; Ullmann U
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():33-8. PubMed ID: 6238931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory evaluation of enoxacin: comparison with norfloxacin and nalidixic acid.
    Teoh-Chan CH; Cowlishaw A; Eley A; Slater G; Greenwood D
    J Antimicrob Chemother; 1985 Jan; 15(1):45-52. PubMed ID: 3156113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A laboratory assessment of ciprofloxacin and comparable antimicrobial agents.
    Shrire L; Saunders J; Traynor R; Koornhof HJ
    Eur J Clin Microbiol; 1984 Aug; 3(4):328-32. PubMed ID: 6237900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo activity of DL-8280, a new oxazine derivative.
    Sato K; Matsuura Y; Inoue M; Une T; Osada Y; Ogawa H; Mitsuhashi S
    Antimicrob Agents Chemother; 1982 Oct; 22(4):548-53. PubMed ID: 6960805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.
    Barry AL; Jones RN
    Antimicrob Agents Chemother; 1984 Jun; 25(6):775-7. PubMed ID: 6234858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.
    Neu HC; Labthavikul P
    Antimicrob Agents Chemother; 1982 Jul; 22(1):23-7. PubMed ID: 6214995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.